The statements regarding Herpafend have not been evaluated by the Food and Drug Administration (FDA). This product is not ...
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment option for patientsVision improvements were seen in both ...
First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multiple myeloma as early as second line ...
Chennai: School education department announced on Monday that public exams for Class XI students are cancelled from this ...
Following the release of the Tamil Nadu School Education Policy (SEP) in August, the state's Department of School Education ...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. today announced positive results from the pivotal Phase 3 EV-303 clinical trial (also known as ...
In the past decade, a quiet and a profound revolution has been taking place within the walls of India's advanced medical ...
T-cell engagers, especially BiTEs, show promise in treating solid tumors by targeting tumor-associated antigens and redirecting T-cell activity. Tarlatamab, targeting DLL3 in SCLC, demonstrated ...
Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation THOUSAND OAKS, Calif., Oct. 17, 2025 ...
Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.
It’s time for the FDA to re-evaluate its decision to authorise Q-Collar, say James Smoliga and Mu Yang A wearable “brain protection” device known as the Q-Collar, which sells for $199 (£149; €170), is ...
Boehringer Ingelheim and Click Therapeutics today shared data from the pivotal Phase III CONVOKE study (NCT05838625) of CT-155 (BI 3972080), an investigational prescription digital therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results